ValuEngine upgraded shares of XOMA (NASDAQ:XOMA) from a sell rating to a hold rating in a research note published on Friday morning.
Several other equities research analysts also recently commented on XOMA. Zacks Investment Research downgraded shares of XOMA from a buy rating to a hold rating in a research note on Wednesday, February 21st. TheStreet upgraded shares of XOMA from an e+ rating to a c- rating in a research note on Wednesday, November 29th. HC Wainwright set a $38.00 price objective on shares of XOMA and gave the stock a buy rating in a research note on Thursday, December 7th. Finally, Wedbush reiterated a buy rating and set a $33.00 price objective on shares of XOMA in a research note on Tuesday, December 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $38.33.
Shares of XOMA (NASDAQ:XOMA) opened at $24.08 on Friday. XOMA has a one year low of $5.27 and a one year high of $37.25. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 2.52. The company has a market cap of $193.15, a price-to-earnings ratio of 32.99 and a beta of 3.03.
A number of hedge funds and other institutional investors have recently bought and sold shares of XOMA. EAM Investors LLC acquired a new position in XOMA during the third quarter valued at $835,000. OxFORD Asset Management LLP acquired a new position in XOMA during the third quarter valued at $543,000. Bank of Montreal Can acquired a new position in XOMA during the fourth quarter valued at $138,000. Acadian Asset Management LLC acquired a new position in XOMA during the fourth quarter valued at $152,000. Finally, IFP Advisors Inc acquired a new position in XOMA during the fourth quarter valued at $581,000. Institutional investors own 39.76% of the company’s stock.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.